XORTX Therapeutics Inc ( ($TSE:XRTX) ) has issued an update. XORTX Therapeutics Inc. announced a change of auditor, appointing Davidson & Company ...

New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

XORTX Therapeutics Inc. is a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. The company is actively involved in creating ...

XORTX to focus on late stage allopurinol intolerant gout program; discussion with FDA planned for first half 2025 regarding ...

IN a recent paper, D. E. Green 1 published values of the potentials of the systems hypoxanthine &rlharr; uric acid, xanthine &rlharr; uric acid, which I had already determined 2.

Guangdong Provincial Key Laboratory of Biotechnology for Plant Development, Guangzhou Key Laboratory of Subtropical Biodiversity and Biomonitoring, Institute of Ecological Science, School of Life ...

For gout, xanthine oxidase (XO) inhibitors are the choice for first-line urate-lowering therapy (ULT) according to the 2020 American College of Rheumatology Guideline for the Management of Gout ...

Our results demonstrate that xanthine oxidase (XO) and aldehyde dehydrogenase 2 (ALDH2), both of which are key GTN-bioactivating enzymes (Doel et al., 2000; Li et al., 2005), are inactivated by GTN ...